Rep. Burgess Vows To Fight FDA Panel Conflict-Of-Interest Restrictions
This article was originally published in The Gray Sheet
Executive SummaryRelaxing conflict-of-interest restrictions for FDA advisory panels will be a top priority for Texas Republican Congressman Michael Burgess during the upcoming reauthorization of device and drug user fee programs, he said Sept. 26.
You may also be interested in...
Details on draft legislation circulating in the House and Senate.
Sponsor of bill that would loosen conflict of interest rules says requiring public release of financial disclosure documents, as one group suggested, may not require a legislative fix.